Search Results
Your search for ,aLl matches 18304 pages
Showing 8551 - 8600NRG1 Gene Fusions Detected at Low Incidence Across Multiple Tumor Types
A consortium of researchers have completed an analysis of a new gene fusion they believe is responsible for the development of a wide spectrum of cancer types. According to the investigators, their studies show that errant gene fusions in neuregulin-1, or NRG1, which are present in about...
Primary Surgery Outcomes in MRI-Based ‘Good-Prognosis’ Rectal Cancer
In a Canadian phase II trial reported in JAMA Oncology, Kennedy et al found a low rate of positive circumferential resection margins after primary surgery in patients with rectal cancer considered to have a ‘good prognosis’ based on magnetic resonance imaging (MRI) criteria. As...
Patient-Reported Outcomes With Salvage Autologous Stem Cell Transplantation vs Nontransplantation in Relapsed Multiple Myeloma
In an analysis of the phase III UK Myeloma X trial reported in the Journal of Clinical Oncology, Ahmedzai et al found that patient-reported outcomes tended to be worse with salvage autologous stem cell transplantation (ASCT) vs nontransplantation consolidation in relapsed multiple myeloma. The...
KEYNOTE-158: Pembrolizumab in Previously Treated Advanced Cervical Cancer
As reported in the Journal of Clinical Oncology by Chung et al, the phase II KEYNOTE-158 trial showed activity of pembrolizumab in previously treated programmed cell death ligand 1 (PD-L1)-positive advanced cervical cancer. The study supported the 2018 accelerated approval of pembrolizumab in this...
ASCO and ASH Release Update to Clinical Practice Guidelines for Use of Erythropoiesis-Stimulating Agents
ASCO and the American Society of Hematology (ASH) have released an update to existing guidelines for the use of erythropoiesis-stimulating agents to manage anemia in patients with cancer. The update was simultaneously published in the Journal of Clinical Oncology and Blood Advances. “The...
Treatment of Patients With Imminently Fatal de Novo Metastatic Cancer
Some patients who died within 1 month of being newly diagnosed with metastatic cancer in the United States received ineffective surgery, chemotherapy, radiotherapy, and hormonal therapy, according to a new study published by Sineshaw et al in JNCI Cancer Spectrum. The study authors said the...
Actionable Pathogenic Variants in a Population-Based Cohort of Patients With Breast or Ovarian Cancer
In a study reported in the Journal of Clinical Oncology, Kurian et al found that approximately one-quarter of women with breast cancer and one-third of those with ovarian cancer underwent cancer genetic testing, and that 8% to 15% of those tested had actionable pathogenic variants. Study Details...
Lenvatinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
In a single-center phase II study reported in the Journal of Clinical Oncology, Tchekmedyian et al found that the multitargeted tyrosine kinase inhibitor lenvatinib was active in progressive recurrent or metastatic adenoid cystic carcinoma. Study Details In the study, 32 evaluable patients at...
American Cancer Society Report Finds Application of Cancer-Reducing Strategies in the United States Is Suboptimal
The latest edition of the American Cancer Society’s (ACS) review on recent cancer prevention and early detection efforts has found that although many strategies have been proven to reduce cancer risk, their application has been suboptimal in the United States, especially in socioeconomically...
Five-Fraction SBRT for Centrally Located, Inoperable NSCLC
In the phase I/II NRG Oncology/RTOG 0813 study reported in the Journal of Clinical Oncology, Bezjak et al found that five-fraction stereotactic body radiotherapy (SBRT) was associated with relatively low rates of serious treatment-related toxicity and good outcomes in patients with centrally...
Niraparib in Late-Line Treatment of Ovarian Cancer
In the phase II QUADRA trial reported in The Lancet Oncology, Moore et al found that the poly(ADP-ribose) polymerase (PARP) inhibitor niraparib was active in fourth- or later-line treatment of ovarian cancer, particularly in patients with homologous recombination deficiency (HRD)-positive,...
Factors Contributing to Improved Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
A newly published Mayo Clinic study has found that a presurgery treatment plan for patients with borderline/locally advanced pancreatic cancer undergoing total neoadjuvant therapy may improve outcomes. The findings were published by Truty et al in Annals of Surgery. The study followed 194...
Paclitaxel or Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Cancer
In the Chinese phase III ESO-Shanghai 1 trial reported in the Journal of Clinical Oncology, Chen et al found that paclitaxel plus fluorouracil did not significantly prolong overall survival vs standard cisplatin plus fluorouracil in definitive concurrent chemoradiotherapy (dCRT) for locally...
Opioid-Related Hospitalizations Among Patients With Cancer in the United States
In a study reported in a research letter in JAMA Oncology, Chua et al found that opioid-related hospitalizations among American patients with cancer are rare, increasing at a very low rate, and consist mostly of hospitalization for nonheroin opioid poisoning. The study analyzed trends and risk...
FDA Expands Pembrolizumab Indication for NSCLC in First-Line Setting
Today, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the first-line treatment of patients with stage III non–small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or those with metastatic NSCLC....
ASCO Announces New Task Force to Address Rural Cancer Care Gap
Yesterday at the National Press Club in Washington, DC, ASCO announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new Rural Cancer Care Task Force will identify opportunities to close the care gap and ...
ELCC 2019: Does Maintenance Immunotherapy Improve Survival in Patients With Advanced SCLC?
Maintenance immunotherapy did not improve survival in patients with extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study presented today by Owonikoko et al at the European Lung Cancer Congress 2019 (Abstract LBA1_PR). Around 60% to 70% of...
ELCC 2019: Immunotherapy in Elderly Patients With Advanced NSCLC
Two studies reported at the European Lung Cancer Congress (ELCC) 2019 provided new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non–small cell lung cancer (NSCLC). Although around half of all people newly diagnosed with NSCLC are elderly (Pallis ...
Lung Cancer Organizations Join Forces to Launch GO2 Foundation for Lung Cancer
Two nonprofit organizations serving the lung cancer community—the Bonnie J. Addario Lung Cancer Foundation (ALCF) and Lung Cancer Alliance (LCA)—have announced they are joining forces as the GO2 Foundation for Lung Cancer. With more than 3 decades of combined expertise, a...
Stromal Tumor–Infiltrating Lymphocytes and Outcomes in Early-Stage HER2-Positive Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Kim and colleagues found that higher levels of stromal tumor–infiltrating lymphocytes (TILs) were associated with better outcomes in patients receiving adjuvant chemotherapy or trastuzumab plus chemotherapy for early-stage...
Researcher Supported by ASCO’s Conquer Cancer Foundation Earns Spot in Clinical Cancer Advances 2019 for Lymphoma Trial
THE WORK of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2019. Visit CONQUER.ORG/CCA for more details. Immunotherapy for Lymphoma AT THE University of Texas MD Anderson Cancer Center in Houston, Sattva S. Neelapu, MD, led...
ASCO Seeks Applicants for Research Grants to Use Data From CancerLinQ Discovery
ASCO recently announced that it is seeking applications for research grants for projects that use data from CancerLinQ Discovery®—an offering of ASCO’s CancerLinQ® initiative—as a source. CancerLinQ Discovery provides curated sets of deidentified data from patients with cancer to academic...
ASCO in Action Policy Podcast Features Exclusive Interviews With Top Leadership at FDA, NCI
OVER THE PAST several months, the ASCO in Action Podcast has secured exclusive interviews with high-ranking officials to discuss health policy issues affecting the United States. In March, the Director of the National Cancer Institute (NCI) and U.S. Food and Drug Administration (FDA) Acting...
Read the Latest Posts on JOP DAiS
THE JOURNAL of Oncology Practice Discussion and Analysis in Short (JOP DAiS) blog provides health-care professionals with concise, to-the-point pieces about the latest information in cancer care delivery. Visit jopblog.org to read new posts, including “Three Must-see Talks From the ASCO Quality...
Help Patients Do More to Cope With Cancer-Related Pain
RELIEVING PAIN is an important part of cancer care, and each patient experiences pain differently. Give your patients the information and tools they need to understand and manage their pain. ASCO Answers offers two helpful products on managing cancer-related pain: a one-page fact sheet or an...
Self-Evaluation App Offers Topic-Specific Information for Learning on the Go
As oncology professionals’ schedules become more demanding, mobile technology is often used to efficiently work on the go. Continued education can be conveniently incorporated into clinicians’ routines with apps such as ASCO eLearning’s newly rebranded Self-Evaluation App, formerly the ASCO MOC...
Carson Leslie Foundation Joins Forces With ASCO’s Conquer Cancer Foundation to Fight Medulloblastoma
Carson Leslie was a kind, popular, lively teen who loved sports and spending time with his family and friends. He was a devoted student at The Covenant School of Dallas, where he was quarterback on the school’s football team, and he was an active member of Grace Bible Church. He shared a special...
Better Techniques Coming to Breast Cancer Screening
BREAST CANCER SCREENING is no longer “just mammography” but involves a growing list of ever more sophisticated techniques that are improving detection, according to Elizabeth Morris, MD, Professor of Radiology, the Larry Norton Chair, and Chief of the Breast Imaging Service at Memorial Sloan...
Biologic Age and Elevated Risk of Breast Cancer
Biologic age—a DNA-based estimate of a person’s age—may be associated with the development of breast cancer, according a report published by Jacob K. Kresovich, PhD, of the National Institute of Environmental Health Sciences (NIEHS), and colleagues in the Journal of the National Cancer Institute.1...
I Was Not Prepared for the Emotional Toll of Cancer
In 1996, an excruciating sore throat sent me first to my primary care physician and then to an ear, nose, and throat specialist, after a suspicious mass was found on the right side of my throat. A biopsy determined that the tumor was squamous cell neck cancer, and additional tests of my neck,...
Vaccine Plus Trastuzumab in Preventing Recurrence of HER2–Low-Expressing Breast Cancer
IN HIGH-RISK patients with breast cancer and low expression of HER2 (HER2 low), a peptide vaccine targeting HER2, combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), and given concurrently with trastuzumab, may help to prevent recurrence. Final analysis of a randomized phase...
Expert Point of View: Michael Morse, MD
FORMAL DISCUSSANT of the abstract presented by Harding et al, Michael Morse, MD, Professor of Medicine at Duke University Medical Center, in Durham, North Carolina, noted that the authors should be commended on a complex dose-escalation strategy that surely required a lot of collaboration among...
Human Gene Therapy: Progress and Oversight
The early debate over the social and ethical implications of gene therapy led the National Institutes of Health (NIH) to establish the Recombinant DNA Advisory Committee in 1974. However, the risks of human gene therapies were largely unknown until 1999, when a patient died of a massive immune...
Opioid Toolkit: Helping Nebraskan Hospitals to Provide Appropriate Pain Management
As the opioid epidemic continues to sweep the United States, providers across Nebraska are facing the challenge of determining the appropriateness of pain treatment options that both meet the needs of the patients and fall within nationally published guidelines. A recent report published by the...
Anti–TIM-3 Antibody Well Tolerated as Monotherapy and in Combination With Anti–PD-L1 Antibody
INITIAL DATA from the ongoing, multicenter, first-in-human, phase Ia/Ib dose-escalation and -expansion study suggest that an anti–T-cell immunoglobulin domain and mucin domain–containing molecule 3 (anti–TIM-3) antibody alone or in combination with immune checkpoint blockade could counter intrinsic ...
Lenvatinib Plus Pembrolizumab Shows Activity in Advanced Urothelial Cancer
THE COMBINATION of lenvatinib plus pembrolizumab has demonstrated antitumor activity in patients with advanced urothelial cancer, including patients receiving later-line treatment. Results of a phase Ib/II trial showed an objective response rate of 25% and a median progression-free survival of 5.4...
Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents
NEW AGENTS for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of...
Harborside’s OncologyGo™ Wins 2019 Mobile Star Award for Innovative Mobile Health-Care Application
Harborside, a market-leading medical communications company (and publisher of The ASCO Post), has announced that OncologyGo™, its free, on-demand oncology video mobile app, has been recognized in the 2019 Mobile Star Awards winter program, hosted by MobileVillage.com. Both Harborside and the app...
Full Disclosure: What Oncologists Must Tell Patients About Their Experience and Training
Informed consent is an important part of delivering quality cancer care. Traditional ethical and legal rules require clinicians to disclose three types of information: (1) the patient’s diagnosis; (2) the nature of the proposed intervention and its intended benefits, risks, and adverse effects;...
Allogeneic Hematopoietic Cell Transplantation and Cell Therapy
As part of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several studies of allogeneic hematopoietic cell transplantation (allo-HCT) and cellular therapy, as used in myelodysplastic syndromes (MDS), acute...
Dana-Farber Launches Young-Onset Colorectal Cancer Center
Dana-Farber/Brigham and Women’s Cancer Center recently announced the launch of the Young-Onset Colorectal Cancer Center in Boston. The Center will provide expert, compassionate, and cutting-edge care to young adult patients with colon and rectal cancer, with a focus on scientific discovery and...
Study Finds Shorter Treatment Course for Rectal Cancer May Actually Improve Outcomes
In patients with locally advanced rectal cancer, the delivery of all radiotherapy and chemotherapy neoadjuvantly—with a shorter course of radiation—may improve the chance of complete response and downstaging over conventional treatment, according to investigators from Washington University, St....
Study Finds Pembrolizumab Active in Advanced Non–Clear Cell Kidney Cancer
IMMUNOTHERAPY WITH the checkpoint inhibitor pembrolizumab may prove to be an effective option for patients with advanced non–clear cell renal cell carcinoma, according to results in cohort B of the KEYNOTE-427 trial, presented at the 2019 Genitourinary Cancers Symposium.1 Response rates were...
Expert Point of View: William Kevin Kelly, DO
Formal discussant of the CheckMate 650 trial, William Kevin Kelly, DO, Professor of Medical Oncology at the Sidney Kimmel Cancer Center and Jefferson Health in Philadelphia, commented on the combination therapy’s toxicity. “The discontinuation of study drug was significant. An important issue is...
Nivolumab Combined With Ipilimumab Shows Activity in Prostate Cancer Subsets
In contrast with melanoma, lung cancer, and kidney cancer, immune checkpoint inhibitor therapy has been disappointing in prostate cancer thus far. Because of success in treating other tumor types, interest remains high in exploring the effect of immunotherapy with checkpoint inhibition in prostate...
Enzalutamide Plus ADT Extends Progression-Free Survival in Metastatic Hormone-Sensitive Prostate Cancer
Adding enzalutamide to androgen-deprivation therapy (ADT) significantly prolonged radiographic progression-free survival in men with metastatic hormone-sensitive prostate cancer, reducing the risk of disease progression or death by 61% compared with ADT plus placebo, according to the results of the ...
CDC Issues Clarification on Guideline for Prescribing Opioids for Chronic Pain in Patients With Cancer and Sickle Cell Disease
ASCO, the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN®) are pleased to acknowledge receipt of a key clarification from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. ...
Skin Cancer 2019: Small Study of Electrochemotherapy for Basal Cell Carcinomas in the Head and Neck Region
Increasing evidence is emerging about the effectiveness of electrochemotherapy in the treatment of basal cell carcinomas in the head and neck region. A study presented by Kis et al at the World Congress on Advanced Treatments and Technologies in Skin Cancer (Skin Cancer 2019) (Poster Board 6) aimed ...
Skin Cancer 2019: Reflectance Confocal Microscopy Plus Optical Coherence Tomography in Diagnosing Suspicious Basal Cell Carcinoma Lesions
The increasing incidence and prevalence of nonmelanoma skin cancers has led to the search for new and more efficient diagnostic imaging and therapy guidance approaches. However, proper selection of therapy requires the precise delineation of skin cancer margins. To address this need, researchers...
KEYNOTE-181: Pembrolizumab vs Chemotherapy in Second-Line Treatment of Advanced Esophageal Cancer
IN THE GLOBAL phase III KEYNOTE-181 trial, pembrolizumab as second-line therapy for advanced esophageal cancer did not improve overall survival in the whole population, vs chemotherapy, but did improve survival for patients with strong expression of programmed cell death ligand 1 (PD-L1),...
